INTRODUCTION AND OBJECTIVES:
The benefit of neoadjuvant chemotherapy (NAC) for patients with locally advanced upper tract urothelial carcinoma (UTUC) remain unclear. The purpose of this study was to access safety and effectiveness of platinum-based NAC for locally advanced UTUC.
METHODS: From Feb 1995 to Sep 2016, we underwent radical nephroureterectomy for consecutive 229 patients with UTUC at a single institute. Of these, we identified 50 patients who received NAC and 179 patients without NAC. We selected pair-matched patients from with and without NAC using propensity score by logistic analysis. We retrospectively evaluated the tumor response, post-therapy pathological down staging and toxicity between pair-matched patients. Variables for propensity score matching included age, sex, clinical TNM stage, diabetes, tumor location. Disease free and overall survivals were evaluated using Kaplan e Meier methods with log e lank test between two groups: those with and without NAC. Multivariate Cox regression analysis was performed for independent factor for overall survival.
RESULTS: We statistically selected pair-matched 45 patients in each group. The regimens in the NAC group were gemcitabine and carboplatin for 31 cases, gemcitabine and cisplatin for 13 cases, or docetaxel, ifosfamide and nedaplatin for 1 cases. There were no significant differences in patient characteristics between the groups. Median follow up periods in NAC and control group were 21 and 39 months. No severe adverse event associated with NAC was observed. The median response rate in NAC group was 39%. Pathological down staging in primary tumor was achieved in 29 (64%) patients, and it was significantly higher compared with control group (n ¼ 11, 24%). Platinum-based NAC for locally advanced UTUC significantly prolonged progression free survival (P ¼ 0.015) and overall survival (P ¼ 0.025). In multivariate Cox regression analysis, NAC was selected as an independent predictor for prolonged overall survival (P ¼ 0.008, HR: 0.25, 95%CI: 0.90-0.70) CONCLUSIONS: Although present data are preliminary, the platinum-based NAC for advanced UTUC seems to have a potential to improve outcomes. Further prospective randomized studies are needed to confirm the benefit of NAC in patients with locally advanced UTUC. Keisuke Shigeta*, Eiji Kikuchi, Keishiro Fukumoto, Nozomi Hayakawa, Takeo Kosaka, Akira Miyajima, Mototsugu Oya, Tokyo, Japan INTRODUCTION AND OBJECTIVES: Our recent findings from a multi-institutional study showed that up to one-third of upper tract urothelial carcinoma (UTUC) patients did not receive any chemotherapeutic treatment (CTx) for disease recurrence after radical nephroureterectomy (RNU) due to their high age, poor performance status (PS), and comorbidity. However, some patients may not have the chance to receive effective systemic CTx simply because of their advanced age. In this study, we attempted to determine the influence of age on the outcomes of CTx in UTUC patients with disease recurrence following RNU.
METHODS: We identified a study population of 226 patients who developed disease recurrence after RNU during the past 15 years at our 14 Japanese institutions. To identify factors that were related to cancer-specific survival (CSS) and overall survival (OS), we performed multivariate analysis using a Cox proportional hazards regression model that included clinicopathological variables. We also analyzed the efficacy of systemic CTx in a subgroup of patients aged >75 years (yr).
RESULTS: After disease recurrence, 145 patients underwent systemic CTx while the remaining 81 received no systemic treatment. Patients aged >75 yr (n¼81) tended to have poor PS (P<0.001) and bone metastasis at the time of disease relapse (P¼0.028) compared with the younger patients (n¼145), while the administration of adjuvant CTx was less frequent (14.8% in patients aged >75 yr vs. 42.1% in those <75 yr, P<0.001). Multivariate analysis in the overall population revealed that the salvage CTx setting was independently related to CSS as well as OS along with poor PS, the presence of liver metastasis, number of recurrence sites, and lymph node involvement in RNU specimens. Meanwhile, age was not selected as an independent factor. In the subgroup analysis on patients >75 yr, we found no significant difference in the clinicopathological backgrounds among patients who received systemic CTx (n¼38) and their counterparts (n¼43). However, CSS rates in patients with systemic CTx were 41.8% at 1 year and 18.6% at 2 years, while those without were significantly decreased to 10.2% and 6.8% (P¼0.001), respectively. A similar difference could be observed in the estimated probability of OS among patients aged >75 yr.
CONCLUSIONS: Survival rates are significantly higher in patients receiving salvage systemic CTx regardless of their age. Age is e950 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
